Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma
- 28 September 2012
- journal article
- clinical trial
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 131 (1), 110-116.e1
- https://doi.org/10.1016/j.jaci.2012.07.047
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Mucosal tissue polyclonal IgE is functional in response to allergen and SEBAllergy, 2010
- Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthmaJournal of Allergy and Clinical Immunology, 2010
- Efficacy of omalizumab in the treatment of nasal polypsThorax, 2010
- Safety and tolerability of omalizumabClinical & Experimental Allergy, 2009
- Enhanced release of IgE-dependent early phase mediators from nasal polyp tissueJournal of Inflammation, 2009
- Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposisJournal of Allergy and Clinical Immunology, 2004
- Enhanced soluble interleukin‐5 receptor alpha expression in nasal polyposisAllergy, 2003
- Nasal polyposis, eosinophil dominated inflammation, and allergyThorax, 2000
- Eosinophilic airway inflammation in nasal polyposisJournal of Allergy and Clinical Immunology, 1999
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992